Dong-A ST held a donation ceremony for growth hormone drugs worth 1 billion won for over 150 children with short stature at its headquarters in Yongdu-dong, Dongdaemun-gu, Seoul, on 7th. Dong-A ST will donate growth hormone products 'Growth Hormone II Injection Cartridge' and 'Growth Hormone II Injection Pen 30IU' to the Hanmaum Social Welfare Foundation. Through this, low-income children with short stature selected through recommendations from pediatric endocrinologists and document reviews will receive growth hormone support for one year. Since 2013, Dong-A ST has donated growth hormones annually, providing growth hormone drugs worth 6.6 billion won to over 1,100 children by last year, enabling them to grow up healthily.
ImmuneOncia, a subsidiary of Yuhan Corporation specializing in the development of immuno-oncology drugs, announced on 7th that it passed the preliminary examination for listing on the KOSDAQ of the Korea Exchange on 6th. As a result, it will embark on the corporate public offering (IPO) process in earnest. Korea Investment & Securities is the underwriter. ImmuneOncia is a company specialized in developing immuno-oncology drugs targeting T cells and macrophages, which are its core technology. The funds raised through the KOSDAQ listing will be primarily invested in clinical development costs and research and development of new pipelines.
Bukwang Pharmaceutical announced on 7th that it will accelerate the expansion of treatments for schizophrenia and bipolar disorder led by the drug 'Latuda' (ingredient name: Lurasidone hydrochloride), along with its recently launched Alzheimer's treatment 'AriPlus Tablets.' AriPlus Tablets, available in 10 mg and 20 mg (ingredient name: Donepezil hydrochloride hydrate + Memantine hydrochloride), were released simultaneously with the application of health insurance coverage on 1st. AriPlus Tablets are a product co-developed by eight companies, including Bukwang Pharmaceutical, and received product approval from the Ministry of Food and Drug Safety last year. Unlike existing treatments, AriPlus Tablets were developed to combine the two ingredients into one tablet for more convenient consumption by patients.
Pharmicell announced on 7th that its project 'Development of acute myocardial infarction stem cell therapy through the discovery of predictive biomarkers and elucidation of mechanisms' has been selected as an excellent early-stage research project by the National Research Foundation of Korea. This project aims to discover biomarkers that can predict the effectiveness of the acute myocardial infarction stem cell therapy (Heart Cell Gram-AI) developed in previous research and to develop a stem cell therapy that enhances its function and clarifies the mechanism of action.
Yuhan Corporation announced on 7th that it signed an agreement with OSANG Healthcare on 6th to collaborate on the global business of blood sugar control probiotics 'DANGCURAC.' DANGCURAC is Yuhan Corporation's probiotic product, the first in South Korea to receive recognition for its blood sugar reduction functionality. Under this agreement, OSANG Healthcare will take charge of the global distribution of DANGCURAC. OSANG Healthcare expects to create synergy with DANGCURAC, as it has chronic disease diagnostic devices as its main products.
The Ministry of Food and Drug Safety announced on 7th that it will establish an online continuous monitoring system to prevent consumer harm caused by illegal distribution of medical devices from overseas direct purchases. Associations, institutions related to medical devices, and five consumer organizations will participate. The Ministry will appoint staff and members of participating organizations as 'consumer medical device monitors' and support concentrated monitoring of domestic and international overseas direct purchase platforms. Last year, major products detected from illegal overseas direct purchases of unapproved medical devices included laser hair removal devices, blood pressure monitors, cupping devices, anti-snoring magnets, and bruxism guards.